Compare PFIS & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFIS | BWAY |
|---|---|---|
| Founded | 1905 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.8M | 450.8M |
| IPO Year | 1998 | N/A |
| Metric | PFIS | BWAY |
|---|---|---|
| Price | $57.05 | $16.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $56.00 | $13.25 |
| AVG Volume (30 Days) | 42.1K | ★ 144.8K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | ★ 493.94 | N/A |
| EPS | ★ 5.88 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.01 | $309.69 |
| Revenue Next Year | $5.85 | $26.21 |
| P/E Ratio | ★ $9.73 | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.39 | $8.59 |
| 52 Week High | $59.43 | $26.63 |
| Indicator | PFIS | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 59.22 |
| Support Level | $49.98 | $14.56 |
| Resistance Level | $57.71 | $16.63 |
| Average True Range (ATR) | 1.34 | 0.71 |
| MACD | -0.08 | 0.41 |
| Stochastic Oscillator | 45.95 | 95.83 |
Peoples Financial Services Corp is a bank holding company operating through its subsidiaries. The bank provides a full range of financial services. Its products and services include checking accounts, business accounts, savings accounts, loan products, money market accounts, mortgages, chip-enabled debit cards, credit card processing, and visa master card and advisory services. Its loan portfolio includes Commercial loans, which consist of commercial, commercial real estate, municipal, and other related tax-free loans; and retail loans, which include residential real estate and other consumer loans. The company mainly operates in the United States in Pennsylvania.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.